

AGENDA

Bellagio Workshop on Accelerating Progress To Eradicate Drug Resistant TB

Purpose of initiative: To bring together actors to advance a unified strategy and promote coordination among global organizations and countries to accelerate access to drug-resistant TB treatments through catalytic financing of innovative drugs, diagnostics and delivery systems.

Expected outputs:

- An agreed bold target or goal in the context of SDG 3.3 and the UNHLM targets on drug resistant
- Explore potential roles of participating organizations towards a launch and identify broader participation of other interested parties

Background:

Introduction of health innovations traditionally follows a milestone approach between R&D, regulatory approval, policy development, adoption and uptake. Given the significant need-gap for safer, faster and highly-effective treatments in the field of DR-TB, and the pipeline of innovative new regimens currently endorsed or in clinical development, it will potentially help save hundreds of thousands of lives if global stakeholders agree to a mechanism to speed progress between the above mentioned milestones and help carry out some necessary activities under common goals and in parallel.

This year is especially significant in view of the rapidly emerging opportunities in the treatment of drug resistant TB. Now is the time to seize the opportunity to turn these scientific and clinical advances into patient centric rapid access to life-saving new therapeutics.

Participants will discuss urgent aspects of the control and ultimate eradication of drug resistant tuberculosis (TB) through marked acceleration of access to and uptake of novel TB therapeutics. Topics will include health benefits of different scenarios and the need for countries and organizations political and technical support to achieve them with a focus on implementation and innovative finance.

Program

Tuesday, July 30

17:45 Opening session, introductions, goals and ambitions

- Opening remarks
- Survivors testimony video (Peru)
- Global market for new DR-TB treatments, impact of novel regimens (McKinsey)

19:30 Dinner and discussion on presentations

Wednesday, July 31

08:00 Breakfast

New hope for DR-TB patients (South Africa, video)

09:00 Recap of evening session, global MDR-TB targets, ambition, progress/status

10:00 Sharing of existing DR-TB work and efforts of participating organizations and brainstorm on cross-pollination possibilities

10:45 Break

Draft work plan presentations by working group leads

11:00 Delivery and program funding and incentivization to address implementation issues and meet global targets

12:00 Advocacy, education and communications to support global level achievement of targets and support countries in their rollout and implementation

13:00 Lunch

14:00 Pricing and financing instruments

15:00-18:00 Working groups (including break)

A. Delivery implementation and advocacy/education/communications

B. Financing instruments for DR-TB treatment including diagnostics and delivery

Thursday, August 1

09:00 Continued discussions of working group and reporting back

10:45 Break

11:00 Summary of outcomes from working groups

11:45 Program areas: targets, leadership, and timelines

13:00 Lunch and continued discussion

14:00 Conclusions, take-back messages, article, events, and next steps

16:00 Meeting close

Participating organizations and country representatives

